Search all trials

Find therapies in clinical trials near you – page 5

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Malignant melanoma+2

Not recruiting

Registered drugNo placebo

Study on Patient Preference for Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Melanoma, Renal Cell Carcinoma, and Lung Cancer Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Malignant melanoma

Not recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Pembrolizumab and Drug Combination for Patients with Stage III Melanoma Eligible for Neoadjuvant Therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Favezelimab

Contact Research Centre

Malignant melanoma

Not recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Pembrolizumab and Tretinoin in Patients with PD-1 Refractory Melanoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Favezelimab

Contact Research Centre

Malignant melanoma+2

Not recruiting

Registered drugNo placebo

Study of E7386 and Pembrolizumab for Patients with Previously Treated Colorectal Cancer, Melanoma, or Hepatocellular Carcinoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Lenvatinib

Contact Research Centre

Malignant melanoma+6

Not recruiting

Registered drugNo placebo

Study of INCB099280 and Ipilimumab for Patients with Advanced Solid Tumors

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Incb099280

Contact Research Centre

Malignant melanoma+7

Not recruiting

Registered drugNo placebo

Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Nivolumab

Contact Research Centre

Malignant melanoma

Not recruiting

Registered drug

Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

Registered drug

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cemiplimab

Contact Research Centre

Malignant melanoma+1

Not recruiting

Registered drugNo placebo

Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Nivolumab

Contact Research Centre

Malignant melanoma+4

Not recruiting

InvestigationalNo placebo

Study of IPN01194 for Adults with Advanced Solid Tumors, Including Melanoma, Head and Neck Cancer, Pancreatic Cancer, and Colorectal Cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ipn01194

Contact Research Centre

Malignant melanoma+18

Not recruiting

Registered drugNo placebo

Study of JK08, Pembrolizumab, and Lenvatinib for Patients with Advanced or Metastatic Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Lenvatinib

Contact Research Centre

Malignant melanoma+12

Not recruiting

Registered drugNo placebo

Study on the Safety and Effects of ATL001 and Nivolumab for Adults with Metastatic or Recurrent Melanoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Atl001

Contact Research Centre

Malignant melanoma+3

Not recruiting

Registered drugNo placebo

Study on PET Tracers [18F]F-AraG and [89Zr]Zr-Df-Crefmirlimab for Evaluating T Cell Activation in Non-Small Cell Lung Cancer Patients

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Nelarabine

Contact Research Centre

Find therapies in clinical trials near you – page 5

79 trials match your criteria

Malignant melanoma+2

Study on Patient Preference for Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Melanoma, Renal Cell Carcinoma, and Lung Cancer Patients

Malignant melanoma

Study on the Safety and Effectiveness of Pembrolizumab and Drug Combination for Patients with Stage III Melanoma Eligible for Neoadjuvant Therapy

Malignant melanoma

Study on the Safety and Effectiveness of Pembrolizumab and Tretinoin in Patients with PD-1 Refractory Melanoma

Malignant melanoma+2

Study of E7386 and Pembrolizumab for Patients with Previously Treated Colorectal Cancer, Melanoma, or Hepatocellular Carcinoma

Malignant melanoma+6

Study of INCB099280 and Ipilimumab for Patients with Advanced Solid Tumors

Malignant melanoma+7

Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

Malignant melanoma

Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

Malignant melanoma+1

Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Malignant melanoma+4

Study of IPN01194 for Adults with Advanced Solid Tumors, Including Melanoma, Head and Neck Cancer, Pancreatic Cancer, and Colorectal Cancer

Malignant melanoma+18

Study of JK08, Pembrolizumab, and Lenvatinib for Patients with Advanced or Metastatic Cancer

Malignant melanoma+12

Study on the Safety and Effects of ATL001 and Nivolumab for Adults with Metastatic or Recurrent Melanoma

Malignant melanoma+3

Study on PET Tracers [18F]F-AraG and [89Zr]Zr-Df-Crefmirlimab for Evaluating T Cell Activation in Non-Small Cell Lung Cancer Patients

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.